Comparative efficacy and safety of medical treatments for the management of overactive bladder: A systematic literature review and mixed treatment comparison

European Urology

Volumn 65, Issue 4, 2014, Pages 755-765

  Maman, Khaled ^a   Aballea, Samuel ^a   Nazir, Jameel ^b   Desroziers, Katia ^a   Neine, Mohamed Elmoctar ^a   Siddiqui, Emad ^b,d   Odeyemi, Isaac ^b   Hakimi, Zalmai ^c  

^a CREATIV CEUTICAL   (France)

^b Astellas Pharma Europe Ltd   (United Kingdom)

^c Astellas Pharma Global Development   (Netherlands)

^d EALING HOSPITAL   (United Kingdom)

Author keywords

Antimuscarinics; Mirabegron; Mixed treatment comparison; Overactive bladder; Systematic reviews

Indexed keywords

ANTIMUSCARINICS; MIRABEGRON; MIXED TREATMENT COMPARISON; OVERACTIVE BLADDER; SYSTEMATIC REVIEWS;

ACETANILIDES; HUMANS; MUSCARINIC ANTAGONISTS; THIAZOLES; URINARY BLADDER, OVERACTIVE;

EID: 84894447797     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2013.11.010     Document Type: Review

References (62)

1. B.T. Haylen, D. de Ridder, R.M. Freeman International Urogynecological Association; International Continence Society An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction Neurourol Urodyn 29 2010 4 20
2. D.E. Irwin, P. Abrams, I. Milsom, Z. Kopp, and K. Reilly Understanding the elements of overactive bladder: questions raised by the EPIC study BJU Int 11 2008 1381 1387
3. A.J. Wein, and R.R. Rackley Overactive bladder: a better understanding of pathophysiology, diagnosis and management J Urol 175 2006 S5 S10
4. K.E. Andersson Pharmacotherapy of the overactive bladder Discov Med 8 2009 118 124
5. J.S. Benner, M.B. Nichol, and E.S. Rovner et al. Patient-reported reasons for discontinuing overactive bladder medication BJU Int 105 2010 1276 1282
6. A. Wagg, G. Compion, A. Fahey, and E. Siddiqui Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience BJU Int 110 2012 1767 1774
7. N. Buser, S. Ivic, T.M. Kessler, A.G. Kessels, and L.M. Bachmann Efficacy and adverse events of antimuscarinics for treating overactive bladder: network meta-analyses Eur Urol 62 2012 1040 1060
8. C. Chapple, V. Khullar, Z. Gabriel, and J.A. Dooley The effects of antimuscarinic treatments in overactive bladder: a systematic review and meta-analysis Eur Urol 48 2005 5 26
9. C.R. Chapple, V. Khullar, Z. Gabriel, D. Muston, C.E. Bitoun, and D. Weinstein The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis Eur Urol 54 2008 543 562
10. G. Novara, A. Galfano, and S. Secco et al. A systematic review and meta-analysis of randomized controlled trials with antimuscarinic drugs for overactive bladder Eur Urol 54 2008 740 764
11. V. Khullar, G. Amarenco, and J.C. Angulo et al. Efficacy and tolerability of mirabegron, a beta(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial Eur Urol 63 2013 283 295
12. D. Moher, A. Liberati, J. Tetzlaff, and D.G. Altman Reprint - preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement Phys Ther 89 2009 873 880
13. T. Lumley Network meta-analysis for indirect treatment comparisons Stat Med 21 2002 2313 2324
14. R.A. Appell, P. Sand, R. Dmochowski, R. Anderson, and N. Zinner Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT study Mayo Clin Proc 76 2001 358 363
15. Astellas Pharma. Data on file: A randomized, double-blind, parallel group, placebo and active controlled, multi-center dose ranging study with the beta-3 agonist YM178 in patients with symptomatic overactive bladder. 178-CL-044 (DRAGON). ClinicalTrials.gov Web site. http://clinicaltrials.gov/show/ NCT00337090.
16. Astellas Pharma. A phase 2, double-blind, placebo-controlled, parallel group study of YM178 in patients with overactive bladder. 178-CL-045. ClinicalTrials.gov Web site. ClinicalTrials.gov/show/ NCT00527033.
17. Astellas Pharma. A randomized, double-blind, parallel group, placebo and active controlled, multicenter study to assess the efficacy and safety of mirabegron in subjects with symptoms of overactive bladder. 178-CL-046 (SCORPIO). ClinicalTrials.gov Web site. http://clinicaltrials.gov/show/ NCT00689104.
18. Astellas Pharma. A phase III, randomised, double-blind, parallel group, placebo controlled, multicenter study to assess the efficacy and safety of mirabegron in subjects with symptoms of overactive bladder. 178-CL-047 (ARIES). ClinicalTrials.gov Web site. http://clinicaltrials.gov/show/NCT00662909.
19. Astellas Pharma. Phase III study of YM178, a double-blind group comparison study in patients with overactive bladder. 178-CL-048. ClinicalTrials.gov Web site. http://clinicaltrials.gov/show/NCT00966004.
20. Astellas Pharma. A phase III, randomized, double-blind, parallel group, placebo controlled, multicenter study to assess the efficacy and safety of the beta-3 agonist mirabegron (25 mg qd and 50 mg qd) in subjects with symptoms of overactive bladder. 178-CL-074 (CAPRICORN). ClinicalTrials.gov Web site. http://clinicaltrials.gov/show/NCT00912964.
21. L. Cardozo, M. Lisec, and R. Millard et al. Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder J Urol 172 2004 1919 1924
22. C. Chapple, P. van Kerrebroeck, and A. Tubaro et al. Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder Eur Urol 52 2007 1204 1212
23. C.R. Chapple, T. Rechberger, and S. Al-Shukri et al. Randomized, double-blind placebo-and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder BJU Int 93 2004 303 310
24. M.S. Choo, J.Z. Lee, and J.B. Lee et al. Efficacy and safety of solifenacin succinate in Korean patients with overactive bladder: a randomised, prospective, double-blind, multicentre study Int J Clin Pract 62 2008 1675 1683
25. F. Chu, N. Smith, and T. Uchida Efficacy and safety of solifenacin succinate 10 mg once daily: a multicenter, phase III, randomized, double-blind, placebo-controlled, parallel-group trial in patients with overactive bladder Curr Ther Res Clin Exp 70 2009 405 420
26. R.R. Dmochowski, P.K. Sand, N.R. Zinner, M.C. Gittelman, G.W. Davila, and S.W. Sanders Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence Urology 62 2003 237 242
27. F. Haab, L. Stewart, and P. Dwyer Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder Eur Urol 45 2004 420 429
28. S. Herschorn, S. Swift, and Z. Guan et al. Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial BJU Int 105 2010 58 66
29. S. Herschorn, J. Heesakkers, D. Castro-Diaz, J.T. Wang, M. Brodsky, and Z. Guan Effects of tolterodine extended release on patient perception of bladder condition and overactive bladder symptoms Curr Med Res Opin 24 2008 3513 3521
30. S. Hill, V. Khullar, J.J. Wyndaele, and K. Lheritier Dose response with darifenacin, a novel once-daily M3 selective receptor antagonist for the treatment of overactive bladder: results of a fixed dose study Int Urogynecol J Pelvic Floor Dysfunct 17 2006 239 247
31. S.A. Kaplan, T. Schneider, J.E. Foote, Z. Guan, M. Carlsson, and J. Gong Superior efficacy of fesoterodine over tolterodine extended release with rapid onset: a prospective, head-to-head, placebo-controlled trial BJU Int 107 2011 1432 1440
32. V. Khullar, S. Hill, K.U. Laval, H.A. Schiotz, U. Jonas, and E. Versi Treatment of urge-predominant mixed urinary incontinence with tolterodine extended release: a randomized, placebo-controlled trial Urology 64 2004 269 275
33. J.G. Lee, J.Y. Hong, and M.S. Choo et al. Tolterodine: as effective but better tolerated than oxybutynin in Asian patients with symptoms of overactive bladder Int J Urol 9 2002 247 252
34. V.W. Nitti, R. Dmochowski, and P.K. Sand et al. Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome J Urol 178 2007 2488 2494
35. D. Staskin, P. Sand, N. Zinner, and R. Dmochowski Once daily trospium chloride is effective and well tolerated for the treatment of overactive bladder: results from a multicenter phase III trial J Urol 178 2007 978 983
36. P. Van Kerrebroeck, K. Kreder, U. Jonas, N. Zinner, and A. Wein Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder Urology 57 2001 414 421
37. O. Yamaguchi, O. Nishizawa, and M. Takeda et al. Efficacy, safety and tolerability of fesoterodine in Asian patients with overactive bladder LUTS 3 2011 43 50
38. O. Yamaguchi, E. Marui, and H. Kakizaki et al. Randomized, double-blind, placebo- and propiverine-controlled trial of the once-daily antimuscarinic agent solifenacin in Japanese patients with overactive bladder BJU Int 100 2007 579 587
39. N. Zinner, J. Susset, M. Gittelman, M. Arguinzoniz, L. Rekeda, and F. Haab Efficacy, tolerability and safety of darifenacin, an M(3) selective receptor antagonist: an investigation of warning time in patients with OAB Int J Clin Pract 60 2006 119 126
40. P. Abrams, L. Cardozo, C. Chapple, D. Serdarevic, K. Hargreaves, and V. Khullar Comparison of the efficacy, safety, and tolerability of propiverine and oxybutynin for the treatment of overactive bladder syndrome Int J Urol 13 2006 692 698
41. Astellas Pharma. A randomized, double-blind, parallel group, proof of concept study of YM178 in comparison with placebo and tolterodine in patients with symptomatic overactive bladder (BLOSSOM). 178-CL-008. ClinicalTrials.gov Web site. http://clinicaltrials.gov/show/NCT01604928.
42. J. Birns, E. Lukkari, and J.G. Malone-Lee A randomized controlled trial comparing the efficacy of controlled-release oxybutynin tablets (10 mg once daily) with conventional oxybutynin tablets (5 mg twice daily) in patients whose symptoms were stabilized on 5 mg twice daily of oxybutynin BJU Int 85 2000 793 798
43. I. But, M.S. Goldstajn, and S. Oreskovic Comparison of two selective muscarinic receptor antagonists (solifenacin and darifenacin) in women with overactive bladder - the SOLIDAR study Coll Antropol 36 2012 1347 1353
44. C.R. Chapple, P. Araño, J.L. Bosch, D. De Ridder, A.E. Kramer, and A.M. Ridder Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled phase 2 dose-finding study BJU Int 93 2004 71 77
45. J. Corcos, R. Casey, and A. Patrick et al. A double-blind randomized dose-response study comparing daily doses of 5, 10 and 15 mg controlled-release oxybutynin: balancing efficacy with severity of dry mouth BJU Int 97 2006 520 527
46. A.C. Diokno, R.A. Appell, P.K. Sand OPERA Study Group Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial Mayo Clin Proc 78 2003 687 695
47. S. Herschorn, L. Stothers, and K. Carlson et al. Tolerability of 5 mg solifenacin once daily versus 5 mg oxybutynin immediate release 3 times daily: results of the VECTOR trial J Urol 183 2010 1892 1898
48. C.H. Ho, T.C. Chang, H.H. Lin, S.P. Liu, K.H. Huang, and H.J. Yu Solifenacin and tolterodine are equally effective in the treatment of overactive bladder symptoms J Formos Med Assoc 109 2010 702 708
49. Y. Homma, J.S. Paick, J.G. Lee, and K. Kawabe Clinical efficacy and tolerability of extended-release tolterodine and immediate-release oxybutynin in Japanese and Korean patients with an overactive bladder: a randomized, placebo-controlled trial BJU Int 92 2003 741 747
50. B. Jacquetin, and J.J. Wyndaele Tolterodine reduces the number of urge incontinence episodes in patients with an overactive bladder Eur J Obstet Gynecol Reprod Biol 98 2001 97 102
51. T.E. Lackner, J.F. Wyman, T.C. McCarthy, M. Monigold, and C. Davey Randomized, placebo-controlled trial of the cognitive effect, safety, and tolerability of oral extended-release oxybutynin in cognitively impaired nursing home residents with urge urinary incontinence J Am Geriatr Soc 56 2008 862 870
52. J.G. Malone-Lee, J. Bernard Walsh, and M.F. Maugourd Tolterodine: a safe and effective treatment for older patients with overactive bladder J Am Geriatr Soc 49 2001 700 705
53. V.W. Nitti, E.S. Rovner, and T. Bavendam Response to fesoterodine in patients with an overactive bladder and urgency urinary incontinence is independent of the urodynamic finding of detrusor overactivity BJU Int 105 2010 1268 1275
54. R. Rackley, J.P. Weiss, E.S. Rovner, J.T. Wang, and Z. Guan Nighttime dosing with tolterodine reduces overactive bladder-related nocturnal micturitions in patients with overactive bladder and nocturia Urology 67 2006 731 736
55. R. Rogers, G. Bachmann, and Z. Jumadilova et al. Efficacy of tolterodine on overactive bladder symptoms and sexual and emotional quality of life in sexually active women Int Urogynecol J Pelvic Floor Dysfunct 19 2008 1551 1557
56. D. Rudy, K. Cline, R. Harris, K. Goldberg, and R. Dmochowski Time to onset of improvement in symptoms of overactive bladder using antimuscarinic treatment BJU Int 97 2006 540 546
57. N.R. Zinner, A. Mattiasson, and S.L. Stanton Efficacy, safety, and tolerability of extended-release once-daily tolterodine treatment for overactive bladder in older versus younger patients J Am Geriatr Soc 50 2002 799 807
58. A. Athanasopoulos, and K. Giannitsas An overview of the clinical use of antimuscarinics in the treatment of overactive bladder Adv Urol 2011 2011 820816
59. V.W. Nitti, V. Khullar, and P. van Kerrebroeck et al. Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies Int J Clin Pract 67 2013 619 632
60. J.G. Malone-Lee, J.B. Walsh, and M.F. Maugourd Tolterodine: a safe and effective treatment for older patients with overactive bladder J Am Geriatr Soc 49 2001 700 705
61. S. Dias, A.J. Sutton, A.E. Ades, and N.J. Welton Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials Med Decis Making 33 2013 607 617
62. S. Dias, A.J. Sutton, N.J. Welton, and A.E. Ades Evidence synthesis for decision making 3: heterogeneity - subgroups, meta-regression, bias, and bias-adjustment Med Decis Making 33 2013 618 640